Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.59 |
| ▸ | MMP2 | P08253 | 4/20 | 0.59 |
| ▸ | MMP9 | P14780 | 4/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.57 |
| ▸ | MEF2D | Q14814 | 3/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | EP300 | Q09472 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.55 |
| ▸ | TUBB | P07437 | 1/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.55 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.55 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.55 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111461 | 0.87 | MMP1 (0.75) | MMP1MMP2MMP9EGFR | |
| SCHEMBL13180844 | 0.85 | HDAC1 (0.74) | MMP1MMP2MMP9HDAC1HDAC2 | |
| SCHEMBL111095 | 0.84 | SMN1; SMN2 (0.74) | MMP1MMP2MMP9EGFR | |
| SCHEMBL2779401 | 0.83 | MEN1 (0.68) | MMP1MMP2MMP9EGFR | |
| SCHEMBL110012 | 0.83 | MEN1 (0.68) | MMP1MMP2MMP9EGFR | |
| SCHEMBL14188338 | 0.82 | HDAC1 (0.79) | HDAC1HDAC2HDAC4HDAC3HDAC7 | |
| SCHEMBL5020771 | 0.82 | HDAC1 (0.79) | HDAC1HDAC2HDAC4HDAC3HDAC7 | |
| SCHEMBL2640602 | 0.81 | HDAC1 (0.66) | MMP1MMP2MMP9HDAC1HDAC2 | |
| SCHEMBL21024846 | 0.81 | MMP1 (0.55) | MMP1MMP2MMP9EGFR | |
| SCHEMBL3228583 | 0.81 | EGFR (0.71) | MMP1MMP2MMP9HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180117051-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-20180117049-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-9839640-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2017-12-12 | — | — | US | disclosed |
| US-8624056-B2 | Halogenated analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD | 2014-01-07 | — | — | US | disclosed |
| US-20130310386-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2013-11-21 | — | — | US | disclosed |
| US-20120059188-A9 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | THE UNIVERSITY OF MELBOURNE (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117049-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | MMP1 10/4885MMP2 239/4885MMP9 205/4885 |
| US-20130310386-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | MMP1 10/4885MMP2 239/4885MMP9 205/4885 |
| US-20120059188-A9 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | MMP1 1/4885MMP2 104/4885MMP9 494/4885 |
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | MMP1 10/4885MMP2 239/4885MMP9 205/4885 |
| US-20180117051-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | MMP1 10/4885MMP2 239/4885MMP9 205/4885 |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | MMP1 1/4885MMP2 104/4885MMP9 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.